Skip Ribbon Commands
Skip to main content


Below is a list of citations of original articles pertaining to research that was conducted as part of the Collaboration for AIDS Vaccine Discovery.
Please click on the title to see more information about the article, read its abstract, and link to the article’s record in PubMed.

In January 2015, the Bill & Melinda Gates Foundation adopted an Open Access policy that enables the unrestricted access and reuse of all peer-
reviewed published research funded, in whole or in part, by the foundation, including any underlying data sets. The action stems from the
commitment to information sharing and transparency.
Learn more here...

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal centerEslamizar LNature Research Journals20211/25/202133495459Link to full-text
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-glycan patch. Wang ZeLife202010/21/202033084569Link to full-text
Structures of Human Antibodies Bound to SARS- CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesBarnes COCell20206/24/202032645326Link to full-text
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Kasturi, S.P.Science Immunology20206/19/202032561559Link to full-text
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelRogers TFScience20206/15/202032540903Link to full-text
Variability of CD4+ Cell Counts in HIV-1-Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine StudySajadi MMJournal of Acquired Immune Deficiency Syndromes20205/1/202031985697Link to full-text
Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Stephenson, K.E. Annual Reviews of Immunology20204/26/202032340576Link to full-text
VSV-displayed HIV-1 envelope identifies broadly neutralizing antibodies class-switched to IgG and IgA. Jia, M.Cell Host Microbe20204/15/202032315598Link to full-text
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?Klasse PJCell Host & Microbe20204/8/202032272076Link to full-text
Estimating the timing of early Simian-Human Immunodeficiency Virus infections: a comparison between Poisson Fitter and Beast. Giorgi, E.E. mBio20203/24/202032209678Link to full-text
Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in RabbitsYang YRJournal of Virology20203/17/2020Link to full-text
Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticityLai, J.I.Vaccine20203/16/202032192810Link to full-text
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisitionGorini GiacomoPlos Pathogens20203/12/2020PMC7093029 Link to full-text
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.Ringe RPJournal of Virology20202/28/202031852794Link to full-text
Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. Bharadwaj, P.Journal of Immunological Methods 20202/15/202032070674Link to full-text
Antibody Fc-glycosylation discriminates between latent and active tuberculosisLu LLJournal of Infectious Diseases20202/15/2020Link to full-text
Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Schommers, P.Cell20202/6/202032004464Link to full-text
Boosting with AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency. Easterhoff, D.Journal of Virology20201/31/202031776278Link to full-text
Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbsSeaman, M.S. Journal of Immunological Methods 20201/7/202031917969 Link to full-text
Phase 1 HIV vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C Env proteinHosseinipour, MClinical Infectious Diseases20201/4/202031900486 Link to full-text
Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability and stability while preserving full neutralization activity. Kerwin, B.A.Journal of Pharmaceutical Sciences20201/2/202031348937Link to full-text
Expression of CD40L by the ALVAC -SIV vector abrogates T cell responses in macaquesSilva de Castro IJournal of Virology20201/2/202031896599Link to full-text
Recombinant HIV-1 vaccine candidates on replication-defective flavivirus vectorGiel-Moloney, M.Scientific Reports201912/19/201931882800Link to full-text
SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.Ringe RPJournal of Virology201912/12/2019Link to full-text
Antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies constrain neutralizing antibody escape pathway. Mielke, D. Frontiers in Immunology201912/11/201931921139Link to full-text
Harnessing Avidity: Quantifying the Entropic and Energetic Effects of Linker Length and Rigidity for Multivalent Binding of Antibodies to HIV-1Einav TCell Systems201911/27/201931668801Link to full-text
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector CellsFisher, LFrontiers in Immunology201911/27/201931827470Link to full-text
An MPER antibody neutralizes HIV-1 using germline features shared among donorsZhang LNature Communications201911/26/201931772165Link to full-text
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.Dubrovskaya VImmunity201911/19/201931732167Link to full-text
Structural basis for broad HIV-1 neutralization by a novel MPER-specific human broadly neutralizing antibody. Pinto, D. Cell Host & Microbe201911/13/201931653484Link to full-text
1 - 30Next